Bristol-myers Squibb Stock News

The U.S. Food and Drug Administration recently acknowledged Bristol Myers Squibb's application for deucravacitinib to treat moderate-to-severe psoriasis.

Bristol Myers Squibb Co. stock falls Friday, underperforms market MarketWatch

11 Dividend Increases To Start 2022 Including A Dividend King

Dublin, Dec. 31, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China''s Dasatinib Market 2021-2025" report has been added to ResearchAndMarkets.com''s offering. Dasatinib, developed by Bristol-Myers Squibb, is an anti-tumor drug. It was first approved by the FDA in 2006 for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic and accelerated phases that are resistant or intolerant to previous treatment with imatinib. In 2011, Dasatinib was approved in China. By 2020, the two manufacturers in China''s Dasatinib market are Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Bristol-Myers Squibb Pharma EEIG. According to the market research, the sales of Dasatinib have increased year by year from 2016 to 2020, with the most significant growth in 2018. The annual growth rate is 48.72 % from CNY51 million in 2017 to CNY75 million in 2018. The main reason for the increase is that China has undertaken an effort to cut healthcare costs, requiring insurance to cover 70% of costs since the national drug price negotiations in 2017.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bristol-Myers Squibb offers a substantial dividend, but that''s far from the only reason that BMY stock is a great investment for 2022. The post Best Stocks for 2022: Bristol-Myers Squibb Will Offer Huge Returns appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now Man Who Called Black Monday: Prepare Now. #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First

Bristol-Myers Squibb offers a substantial dividend, but that's far from the only reason that BMY stock is a great investment for 2022. The post Best Stocks for 2022: Bristol-Myers Squibb Will Offer Hu

The pharma/biotech industry is out of favor right now, which is why attractive investment opportunities exist. Bristol-Myers Squibb and Merck both look like solid picks trading at undemanding valuatio

We provide a summary of upcoming ex-dividend dates in a quick reference table.

10 Dividend Growth Stocks For December 2021

Bristol Myers Squibb (BMY) closed the most recent trading day at $62.35, moving +0.1% from the previous trading session.

Bristol Myers' most recent Q3 results beat analyst estimates on both the top and bottom lines. Shares of Bristol Myers are trading with a blended P/E of just 8.21x.

Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching

Dividend investors could be interested in the following stocks, since they offer much higher dividend yields than the S&P 500 Index. The dividend of the benchmark index yields 1.25% as of the close of